← Back to headlines
Apnimed Seeks $160M IPO for Sleep Apnoea Drug Development
Apnimed is reportedly scouting a $160 million initial public offering to fund the late-stage development of its sleep apnoea pill.
28 Jul, 11:26 — 28 Jul, 11:26
Sources
Showing 1 of 1 sources
